AstraZeneca Study of AZD1222

AZD1222 is an investigational vaccine being developed by AstraZeneca to prevent COVID-19, the disease caused by the SARS-CoV-2 virus.

The vaccine is based on a weakened version of a common cold (adenovirus) virus. The adenovirus vaccine has been changed so that it can’t replicate inside your body. It presents part of the COVID-19 spike protein to the body so that an immune response can be made to it. The purpose of the study is to test how well the investigational vaccine works at preventing COVID-19 disease and how safe it is.

Visit ClinicalTrials.gov - NCT04516746 for additional details about the AstraZeneca COVID-19 vaccine clinical study.

Together we can help end uncertainty. Join us.

We need your help to keep learning and improving vaccines against COVID-19. We made history with safe and effective vaccines and we’ll keep working as long as there are people to protect, variants emerging, and research answers needed to end this pandemic. To participate:

  • Fill out the survey again so we have your most current information to match you with a study, even if you filled it out previously!
  • If you haven’t registered to volunteer before, sign up today. There’s still a lot we can do together for those we love.

Volunteer

Content last reviewed on April 14, 2021